As Europe has been significantly impacted by the Covid-19 pandemic, a substantial amount of clinical research is currently focused on identifying effective therapies and vaccines. GlobalData analysed the Covid-19 clinical trials landscape in Europe with a view to identifying key…
Vaxart’s COVID-19 Vaccine Candidate Tapped for Operation Warp Speed Primate Study
One month after Vaxart announced the selection of its lead vaccine candidate for COVID-19, the Bay Area-based company said it has been selected to participate in the U.S. government’s Operation Warp Speed program. The South San Francisco company said this…
Yumanity and Merck Ink $500 Million+ Deal for Neurodegenerative Diseases
Yumanity Therapeutics and Merck signed a strategic research and license deal for two Yumanity programs. The two preclinical programs are for amyotrophic lateral sclerosis (ALS) and frontotemporal lobar dementia (FTLD). Under the terms of the agreement, Merck gains exclusive rights…
FDA Approves Phase III Study of Fulcrum’s Losmapimod in COVID-19
Shares of Fulcrum Therapeutics were up more than 14% in premarket trading after the company announced it will begin the Phase LOSVID III study to assess losmapimod as a potential treatment of COVID-19. This morning Cambridge, Mass.-based Fulcrum said the…
New Data Shows 718 Pipeline Drugs Now Associated with COVID-19
New information released Tuesday by GlobalData showed that there are now more than 718 pipeline drugs associated with COVID-19. In addition, 70% of these products are in the discovery or preclinical stages. “These drugs include combinations of novel agents and…
Clinical Trials Are Starting Back Up, but Some Future Approvals May be Delayed
As the COVID-19 pandemic ramped up in March, April and May around the globe, numerous clinical trials for other diseases were paused in order to free up clinics and hospitals as well as to decrease the risk to patients. If…
Merck’s Experimental Pneumonia Vaccine Hits the Mark in Two Phase III Studies
Merck’s investigational pneumonia vaccine, V114, hit the mark in two Phase III studies, including one involving adult HIV patients. V114, Merck’s investigational 15-valent pneumococcal conjugate vaccine, was assessed in two late-stage studies. The PNEU-WAY trial studied the vaccine in adults…
Evelo Stock Soars After Asset Tapped for Phase II/III COVID-19 Study in the U.K.
Shares of Evelo Biosciences were up more than 25% in premarket trading after the company announced its investigational asset EDP1815 will be included in the Phase II/III TACTIC-E COVID-19-focused clinical trial for conducted by Cambridge University Hospitals NHS Foundation Trust.…
Myovant’s Relugolix Combo Hits the Mark in Endometriosis, Heads to FDA for Prostate Cancer
Myovant announced topline results from SPIRIT 1, the second Phase III trial of once-daily relugolix combination therapy in women with pain linked with endometriosis. The drug combination met its co-primary efficacy endpoints as well as all seven key secondary endpoints.…
Faster nod for clinical trials of all drugs and vaccines soon
A committee led by cabinet secretary Rajiv Gauba has also decided to set up a nodal coordination committee to ensure expeditious disposal of all applications with the decision binding on all regulators. “The proposal was cleared by the committee in…
